The prevalence of adverse cardiometabolic responses to exercise training with evidence-based practice is low.

Diabetes Metab Syndr Obes

Department of Movement Sciences, WWAMI Medical Education Program, University of Idaho, Moscow, ID, USA.

Published: February 2015

Background: The purpose of this study was to determine the prevalence of individuals who experienced exercise-induced adverse cardiometabolic response (ACR), following an evidence-based, individualized, community exercise program.

Methods: Prevalence of ACR was retrospectively analyzed in 332 adults (190 women, 142 men) before and after a 14-week supervised community exercise program. ACR included an exercise training-induced increase in systolic blood pressure of ≥10 mmHg, increase in plasma triglycerides (TG) of >37.0 mg/dL (≥0.42 mmol/L), or decrease in high-density lipoprotein cholesterol (HDL-C) of >4.0 mg/dL (0.12 mmol/L). A second category of ACR was also defined - this was ACR that resulted in a metabolic syndrome component (ACR-risk) as a consequence of the adverse response.

Results: According to the above criteria, prevalence of ACR between baseline and post-program was systolic blood pressure (6.0%), TG (3.6%), and HDL-C (5.1%). The prevalence of ACR-risk was elevated TG (3.2%), impaired fasting blood glucose (2.7%), low HDL-C (2.2%), elevated waist circumference (1.3%), and elevated blood pressure (0.6%).

Conclusion: Evidence-based practice exercise programming may attenuate the prevalence of exercise training-induced ACR. Our findings provide important preliminary evidence needed for the vision of exercise prescription as a personalized form of preventative medicine to become a reality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319718PMC
http://dx.doi.org/10.2147/DMSO.S76880DOI Listing

Publication Analysis

Top Keywords

blood pressure
12
adverse cardiometabolic
8
evidence-based practice
8
community exercise
8
prevalence acr
8
exercise training-induced
8
systolic blood
8
exercise
7
acr
7
prevalence
6

Similar Publications

Background: Although anthracycline-related cardiotoxicity is widely studied, only a limited number of echocardiographic studies have assessed cardiac function in breast cancer survivors (BCSs) beyond ten years from anthracycline treatment, and the knowledge of long-term cardiorespiratory fitness (CRF) in this population is scarce. This study aimed to compare CRF assessed as peak oxygen uptake (V̇O), cardiac morphology and function, and cardiovascular (CV) risk factors between long-term BCSs treated with anthracyclines and controls with no history of cancer.

Methods: The CAUSE (Cardiovascular Survivors Exercise) trial included 140 BCSs recruited through the Cancer Registry of Norway, who were diagnosed with breast cancer stage II to III between 2008 and 2012 and had received treatment with epirubicin, and 69 similarly aged activity level-matched controls.

View Article and Find Full Text PDF

Purpose: We sought to investigate the expression of MALAT1, plasma brain natriuretic peptide, and Tei index in sepsis-induced myocardial injury.

Methods: The current retrospective analysis focused on 146 sepsis patients admitted to our hospital from February 2021 to March 2023. Based on the presence or absence of myocardial injury, the patients were divided into two groups: the sepsis group (n = 80) and the sepsis-induced myocardial injury group (n = 66).

View Article and Find Full Text PDF

Background: Although surviving sepsis campaign (SSC) guidelines are the standard for sepsis and septic shock management, outcomes are still unfavourable. Given that perfusion pressure in sepsis is heterogeneous among patients and within the same patient; we evaluated the impact of individualized hemodynamic management via the transcranial Doppler (TCD) pulsatility index (PI) on mortality and outcomes among sepsis-induced encephalopathy (SIE) patients.

Methods: In this prospective, single-center randomized controlled study, 112 patients with SIE were randomly assigned.

View Article and Find Full Text PDF

Long-term efficacy of Mirabegron-anticholinergic combination in paediatric neurogenic bladder.

J Pediatr Urol

January 2025

Department of Women and Children's Health, School of Life Course Sciences, Kings College London, London, UK; Children's Bladder Service, Evelina London Children's Hospital, Westminster Bridge Road, London, SE1 7EH, UK.

Introduction: The Mirabegron-anticholinergic (MAC) combination has proven effective as a step-up strategy in managing paediatric neurogenic bladder following anticholinergic medication and botulinum toxin (BTX) therapy. This study assesses the long-term efficacy of MAC in children with neurogenic bladder.

Patients And Methods: A retrospective chart review was conducted from 2015 to 2023, including consecutive paediatric patients receiving Mirabegron (25/50 mg) with an anticholinergic agent (solifenacin 16, tolterodine 7, oxybutynin 7, trospium 1).

View Article and Find Full Text PDF

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) reportedly decreased the new-onset atrial arrhythmias in patients with type-2 diabetes (T2DM) or heart failure (HF). This study examined the impact of SGLT2is on catheter ablation for atrial fibrillation (AF) in HF patients without T2DM.

Methods: Persistent AF (PeAF) and HF (N-terminal prohormone of brain natriuretic peptide, NT-proBNP ≥400 pg/ml) patients without T2DM undergoing catheter ablation were prospectively enrolled (n = 102).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!